The role of cytokines in the pathogenesis of rheumatoid arthritis - Practical and potential application of cytokines as biomarkers and targets of personalized therapy

Cytokine

Volumn 76, Issue 2, 2015, Pages 527-536

  Brzustewicz, Edyta ^a   Bryl, Ewa ^a  

^a Department of Pathology and Experimental Rheumatology ^*  (Poland)

Author keywords

BDMARD; Biological treatment; Biomarker; Cytokines; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; AMG 714; ANTIRHEUMATIC AGENT; APILIMOD; BIOLOGICAL MARKER; BRODALUMAB; CANAKINUMAB; CERTOLIZUMAB PEGOL; CYTOKINE; DENOSUMAB; ETANERCEPT; GAMMA INTERFERON; GOLIMUMAB; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 17; INTERLEUKIN 6; IXEKIZUMAB; OSTEOCLAST DIFFERENTIATION FACTOR; OSTEOPROTEGERIN; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SARILUMAB; SECUKIZUMAB; SIRUKUMAB; TOCILIZUMAB; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; MONOCLONAL ANTIBODY;

ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; CARTILAGE CELL; CELL ACTIVATION; DRUG EFFICACY; DRUG POTENCY; DRUG TARGETING; HUMAN; IMMUNOPATHOGENESIS; OSTEOCLAST; OSTEOLYSIS; PANNUS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEIN TARGETING; REVIEW; RHEUMATOID ARTHRITIS; TH1 CELL; TH17 CELL; TH2 CELL; TH22 CELL; ARTHRITIS, RHEUMATOID; METABOLISM; PATHOPHYSIOLOGY; PERSONALIZED MEDICINE; PHYSIOLOGY;

ANTIBODIES, MONOCLONAL; ARTHRITIS, RHEUMATOID; BIOMARKERS; CYTOKINES; HUMANS; PRECISION MEDICINE;

EID: 84943821219     PISSN: 10434666     EISSN: 10960023     Source Type: Journal    
DOI: 10.1016/j.cyto.2015.08.260     Document Type: Review

References (72)

1. McInnes I.B., Schett G. The pathogenesis of rheumatoid arthritis. N Engl J Med 2011, 365(23):2205-2219.
2. Selmi C., Generali E., Massarotti M., Bianchi G., Sciré C.A. New treatments for inflammatory rheumatic disease. Immunol Res 2014, 60(2-3):277-288.
3. Astry B., Harberts E., Moudgil K.D. A cytokine-centric view of the pathogenesis and treatment of autoimmune arthritis. J Interferon Cytokine Res 2011, 31(12):927-940.
4. Firestein G.S. Evolving concepts of rheumatoid arthritis. Nature 2003, 423(6937):356-361.
5. Davis J. Cytokine biomarkers and the promise of personalized therapy in rheumatoid arthritis 2009, vol. 5:143-146. Reumatologia Clinica, Rochester, Minnesote.
6. Brennan F.M., McInnes I.B. Evidence that cytokines play a role in rheumatoid arthritis. J Clin Invest 2008, 118(11):3537-3545.
7. Aletaha D., Neogi T., Silman A.J., Funovits J., Felson D.T., Bingham C.O., Birnbaum N.S., Burmester G.R., Bykerk V.P., Cohen M.D., et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010, 62(9):2569-2581.
8. Smolen J.S., Aletaha D., Grisar J., Redlich K., Steiner G., Wagner O. The need for prognosticators in rheumatoid arthritis. Biological and clinical markers: where are we now?. Arthritis Res Ther 2008, 10(3):208.
9. Bas S., Perneger T.V., Seitz M., Tiercy J.M., Roux-Lombard P., Guerne P.A. Diagnostic tests for rheumatoid arthritis: comparison of anti-cyclic citrullinated peptide antibodies, anti-keratin antibodies and IgM rheumatoid factors. Rheumatology (Oxford) 2002, 41(7):809-814.
10. Haque M., Fino K., Lei F., Xiong X., Song J. Utilizing regulatory T cells against rheumatoid arthritis. Front Oncol 2014, 4:209.
11. Deane K.D. Preclinical rheumatoid arthritis (autoantibodies): an updated review. Curr Rheumatol Rep 2014, 16(5):419.
12. Firestein G.S. The disease formerly known as rheumatoid arthritis. Arthritis Res Ther 2014, 16(3):114.
13. Kim H.R. Anti-citrullinated protein antibodies in rheumatoid arthritis: a bridge between genetic predisposition and autoimmunity. Korean J Intern Med 2013, 28(1):25-28.
14. Kosmaczewska A., Swierkot J., Ciszak L., Szteblich A., Chrobak A., Karabon L., Partyka A., Szechinski J., Wiland P., Frydecka I. Patients with the most advanced rheumatoid arthritis remain with Th1 systemic defects after TNF inhibitors treatment despite clinical improvement. Rheumatol Int 2014, 34(2):243-253.
15. Cope A.P. T cells in rheumatoid arthritis. Arthritis Res Ther 2008, 10(suppl 1):S1.
16. Komatsu N., Takayanagi H. Arthritogenic T cells in autoimmune arthritis. Int J Biochem Cell Biol 2015, 58:92-96.
17. Pawłowska J., Smoleńska Z., Witkowski J., Bryl E.M. Different pattern of T-cell subpopulations in peripheral blood of patients with rheumatoid arthritis at various stages of disease development. Pol Arch Med Wewn 2014, 124(1-2):43-50.
18. Smoleńska Z., Pawłowska J., Daca A., Soroczyńska-Cybula M., Witkowski J., Bryl E.M. Disease activity in patients with long-lasting rheumatoid arthritis is associated with changes in peripheral blood lymphocyte subpopulations. Pol Arch Med Wewn 2012, 122(12):591-598.
19. Chizzolini C., Dayer J.M., Miossec P. Cytokines in chronic rheumatic diseases: is everything lack of homeostatic balance?. Arthritis Res Ther 2009, 11(5):246.
20. Stenken J.A., Poschenrieder A.J. Bioanalytical chemistry of cytokines - a review. Anal Chim Acta 2015, 853:95-115.
21. Vervoordeldonk M.J., Tak P.P. Cytokines in rheumatoid arthritis. Curr Rheumatol Rep 2002, 4(3):208-217.
22. Zhang L., Li J.M., Liu X.G., Ma D.X., Hu N.W., Li Y.G., Li W., Hu Y., Yu S., Qu X., et al. Elevated Th22 cells correlated with Th17 cells in patients with rheumatoid arthritis. J Clin Immunol 2011, 31(4):606-614.
23. Gerli R., Bistoni O., Russano A., Fiorucci S., Borgato L., Cesarotti M.E., Lunardi C. In vivo activated T cells in rheumatoid synovitis. Analysis of Th1- and Th2-type cytokine production at clonal level in different stages of disease. Clin Exp Immunol 2002, 129(3):549-555.
24. Miossec P., van den Berg W. Th1/Th2 cytokine balance in arthritis. Arthritis Rheum 1997, 40(12):2105-2115.
25. Dinarello C.A. Proinflammatory cytokines. Chest 2000, 118(2):503-508.
26. Tayal V., Kalra B.S. Cytokines and anti-cytokines as therapeutics - an update. Eur J Pharmacol 2008, 579(1-3):1-12.
27. Meyer P.W., Hodkinson B., Ally M., Musenge E., Wadee A.A., Fickl H., Tikly M., Anderson R. Circulating cytokine profiles and their relationships with autoantibodies, acute phase reactants, and disease activity in patients with rheumatoid arthritis. Mediators Inflamm 2010, 2010:158514.
28. Steiner G., Tohidast-Akrad M., Witzmann G., Vesely M., Studnicka-Benke A., Gal A., Kunaver M., Zenz P., Smolen J.S. Cytokine production by synovial T cells in rheumatoid arthritis. Rheumatology (Oxford) 1999, 38(3):202-213.
29. Monaco C., Nanchahal J., Taylor P., Feldmann M. Anti-TNF therapy: past, present and future. Int Immunol 2015, 27(1):55-62.
30. Nozawa K., Fujishiro M., Takasaki Y., Sekigawa I. Inhibition of rheumatoid arthritis by blocking connective tissue growth factor. World J Orthop 2014, 5(5):653-659.
31. Smolen J.S., Aletaha D., Koeller M., Weisman M.H., Emery P. New therapies for treatment of rheumatoid arthritis. Lancet 2007, 370(9602):1861-1874.
32. Singh J.A., Christensen R., Wells G.A., Suarez-Almazor M.E., Buchbinder R., Lopez-Olivo M.A., Ghogomu E.T., Tugwell P. A network meta-analysis of randomized controlled trials of biologics for rheumatoid arthritis: a Cochrane overview. CMAJ 2009, 181(11):787-796.
33. Venkatesha S.H., Dudics S., Acharya B., Moudgil K.D. Cytokine-modulating strategies and newer cytokine targets for arthritis therapy. Int J Mol Sci 2014, 16(1):887-906.
34. Scheller J., Chalaris A., Schmidt-Arras D., Rose-John S. The pro- and anti-inflammatory properties of the cytokine interleukin-6. Biochim Biophys Acta 2011, 1813(5):878-888.
35. Vivar N., Van Vollenhoven R.F. Advances in the treatment of rheumatoid arthritis. F1000Prime Rep 2014, 6:31.
36. Krausz S., Boumans M.J., Gerlag D.M., Lufkin J., van Kuijk A.W., Bakker A., de Boer M., Lodde B.M., Reedquist K.A., Jacobson E.W., et al. Brief report: a phase IIa, randomized, double-blind, placebo-controlled trial of apilimod mesylate, an interleukin-12/interleukin-23 inhibitor, in patients with rheumatoid arthritis. Arthritis Rheum 2012, 64(6):1750-1755.
37. Cicuttini F.M., Byron K.A., Maher D., Wootton A.M., Muirden K.D., Hamilton J.A. Serum IL-4, IL-10 and IL-6 levels in inflammatory arthritis. Rheumatol Int 1995, 14(5):201-206.
38. Kronenberg M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu Rev Immunol 2005, 23:877-900.
39. Brown M.A. IL-4 production by T cells: you need a little to get a lot. J Immunol 2008, 181(5):2941-2942.
40. Gonzalo-Gil E., Galindo-Izquierdo M. Role of transforming growth factor-beta (TGF) beta in the physiopathology of rheumatoid arthritis. Reumatol Clin 2014, 10(3):174-179.
41. Peck A., Mellins E.D. Precarious balance: Th17 cells in host defense. Infect Immun 2010, 78(1):32-38.
42. Miao J., Zhang K., Lv M., Li Q., Zheng Z., Han Q., Guo N., Fan C., Zhu P. Circulating Th17 and Th1 cells expressing CD161 are associated with disease activity in rheumatoid arthritis. Scand J Rheumatol 2014, 43(3):194-201.
43. Nadkarni S., Mauri C., Ehrenstein M.R. Anti-TNF-alpha therapy induces a distinct regulatory T cell population in patients with rheumatoid arthritis via TGF-beta. J Exp Med 2007, 204(1):33-39.
44. Tukaj S., Kotlarz A., Jóźwik A., Smoleńska Z., Bryl E., Witkowski J.M., Lipińska B. Cytokines of the Th1 and Th2 type in sera of rheumatoid arthritis patients; correlations with anti-Hsp40 immune response and diagnostic markers. Acta Biochim Pol 2010, 57(3):327-332.
45. Afzali B., Lombardi G., Lechler R.I., Lord G.M. The role of T helper 17 (Th17) and regulatory T cells (Treg) in human organ transplantation and autoimmune disease. Clin Exp Immunol 2007, 148(1):32-46.
46. Hirota K., Hashimoto M., Yoshitomi H., Tanaka S., Nomura T., Yamaguchi T., Iwakura Y., Sakaguchi N., Sakaguchi S. T cell self-reactivity forms a cytokine milieu for spontaneous development of IL-17+ Th cells that cause autoimmune arthritis. J Exp Med 2007, 204(1):41-47.
47. Roeleveld D.M., Koenders M.I. The role of the Th17 cytokines IL-17 and IL-22 in Rheumatoid Arthritis pathogenesis and developments in cytokine immunotherapy. Cytokine 2014.
48. Bartok B., Firestein G.S. Fibroblast-like synoviocytes: key effector cells in rheumatoid arthritis. Immunol Rev 2010, 233(1):233-255.
49. Itonaga I., Fujikawa Y., Sabokbar A., Murray D.W., Athanasou N.A. Rheumatoid arthritis synovial macrophage-osteoclast differentiation is osteoprotegerin ligand-dependent. J Pathol 2000, 192(1):97-104.
50. Atkins G.J., Kostakis P., Vincent C., Farrugia A.N., Houchins J.P., Findlay D.M., Evdokiou A., Zannettino A.C. RANK expression as a cell surface marker of human osteoclast precursors in peripheral blood, bone marrow, and giant cell tumors of bone. J Bone Miner Res 2006, 21(9):1339-1349.
51. Fardellone P., Séjourné A., Paccou J., Goëb V. Bone remodelling markers in rheumatoid arthritis. Mediators Inflamm 2014, 2014:484280.
52. Niu X., Chen G. Clinical biomarkers and pathogenic-related cytokines in rheumatoid arthritis. J Immunol Res 2014, 2014:698192.
53. Kay J., Morgacheva O., Messing S.P., Kremer J.M., Greenberg J.D., Reed G.W., Gravallese E.M., Furst D.E. Clinical disease activity and acute phase reactant levels are discordant among patients with active rheumatoid arthritis: acute phase reactant levels contribute separately to predicting outcome at one year. Arthritis Res Ther 2014, 16(1):R40.
54. Heard B.J., Rosvold J.M., Fritzler M.J., El-Gabalawy H., Wiley J.P., Krawetz R.J. A computational method to differentiate normal individuals, osteoarthritis and rheumatoid arthritis patients using serum biomarkers. J R Soc Interface 2014, 11(97):20140428.
55. Deane K.D., O'Donnell C.I., Hueber W., Majka D.S., Lazar A.A., Derber L.A., Gilliland W.R., Edison J.D., Norris J.M., Robinson W.H., et al. The number of elevated cytokines and chemokines in preclinical seropositive rheumatoid arthritis predicts time to diagnosis in an age-dependent manner. Arthritis Rheum 2010, 62(11):3161-3172.
56. Smolen J.S., Landewé R., Breedveld F.C., Buch M., Burmester G., Dougados M., Emery P., Gaujoux-Viala C., Gossec L., Nam J., et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014, 73(3):492-509.
57. Breedveld F. TNF antagonists opened the way to personalized medicine in rheumatoid arthritis. Mol Med 2014, 20(suppl 1):S7-S9.
58. Smolen J.S., Aletaha D. Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol 2015.
59. Feldmann M., Maini R.N. Anti-TNF therapy, from rationale to standard of care: what lessons has it taught us?. J Immunol 2010, 185(2):791-794.
60. van Vollenhoven R.F., Geborek P., Forslind K., Albertsson K., Ernestam S., Petersson I.F., Chatzidionysiou K., Bratt J. Group Ss: conventional combination treatment versus biological treatment in methotrexate-refractory early rheumatoid arthritis: 2 year follow-up of the randomised, non-blinded, parallel-group Swefot trial. Lancet 2012, 379(9827):1712-1720.
61. De Stefano R., Frati E., Nargi F., Baldi C., Menza L., Hammoud M., Galeazzi M. Comparison of combination therapies in the treatment of rheumatoid arthritis: leflunomide-anti-TNF-alpha versus methotrexate-anti-TNF-alpha. Clin Rheumatol 2010, 29(5):517-524.
62. Keystone E.C., Genovese M.C., Hall S., Miranda P.C., Bae S.C., Palmer W., Wu Z., Xu S., Hsia E.C. Golimumab in patients with active rheumatoid arthritis despite methotrexate therapy: results through 2 years of the GO-FORWARD study extension. J Rheumatol 2013, 40(7):1097-1103.
63. Punzi L., Lapadula G., Mathieu A. Efficacy and safety of certolizumab pegol in rheumatoid arthritis: meeting rheumatologists' requirements in routine clinical practice. BioDrugs 2014, 28(suppl 1):S25-S37.
64. Genovese M.C., Bathon J.M., Martin R.W., Fleischmann R.M., Tesser J.R., Schiff M.H., Keystone E.C., Wasko M.C., Moreland L.W., Weaver A.L., et al. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum 2002, 46(6):1443-1450.
65. Bryl E., Vallejo A.N., Matteson E.L., Witkowski J.M., Weyand C.M., Goronzy J.J. Modulation of CD28 expression with anti-tumor necrosis factor alpha therapy in rheumatoid arthritis. Arthritis Rheum 2005, 52(10):2996-3003.
66. Kosmaczewska A., Swierkot J., Ciszak L., Wiland P. The role of Th1, Th17, and Treg cells in the pathogenesis of rheumatoid arthritis including anti-inflammatory action of Th1 cytokines. Postepy Hig Med Dosw (Online) 2011, 65:397-403.
67. Blank N., Max R., Schiller M., Briem S., Lorenz H.M. Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis. Rheumatology (Oxford) 2009, 48(4):440-441.
68. Navarro-Millán I., Sattui S.E., Curtis J.R. Systematic review of tumor necrosis factor inhibitor discontinuation studies in rheumatoid arthritis. Clin Ther 2013, 35(11):1850-1861. e1851.
69. Al-Shakarchi I., Gullick N.J., Scott D.L. Current perspectives on tocilizumab for the treatment of rheumatoid arthritis: a review. Patient Prefer Adherence 2013, 7:653-666.
70. Magyari L., Varszegi D., Kovesdi E., Sarlos P., Farago B., Javorhazy A., Sumegi K., Banfai Z., Melegh B. Interleukins and interleukin receptors in rheumatoid arthritis: research, diagnostics and clinical implications. World J Orthop 2014, 5(4):516-536.
71. Parida J.R., Misra D.P., Wakhlu A., Agarwal V. Is non-biological treatment of rheumatoid arthritis as good as biologics?. World J Orthop 2015, 6(2):278-283.
72. Campbell J., Lowe D., Sleeman M.A. Developing the next generation of monoclonal antibodies for the treatment of rheumatoid arthritis. Br J Pharmacol 2011, 162(7):1470-1484.